83918-28-9 Usage
Uses
Used in Cleaning Products:
2-(sec-Butyl-cyclohexyl-amino)-ethanol is used as a surfactant and emulsifier for its ability to form stable emulsions and reduce the surface tension of liquids, enhancing the cleaning efficiency of various formulations.
Used in Personal Care Products:
In the personal care industry, 2-(sec-Butyl-cyclohexyl-amino)-ethanol serves as an emulsifier and dispersant, contributing to the stability and performance of products such as creams, lotions, and shampoos.
Used in Metalworking Fluids:
2-(sec-Butyl-cyclohexyl-amino)-ethanol is used as a corrosion inhibitor in metalworking fluids, protecting metal surfaces from corrosion and wear during manufacturing processes.
Used in Lubricant Formulations:
Its corrosion inhibiting properties also make 2-(sec-Butyl-cyclohexyl-amino)-ethanol suitable for use in lubricant formulations, where it helps to extend the life of machinery and reduce maintenance requirements.
Used in Various Industrial Formulations:
Due to its amphiphilic nature, 2-(sec-Butyl-cyclohexyl-amino)-ethanol functions as a wetting agent, dispersant, and stabilizer in a variety of industrial applications, improving the performance and stability of formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 83918-28-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,9,1 and 8 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 83918-28:
(7*8)+(6*3)+(5*9)+(4*1)+(3*8)+(2*2)+(1*8)=159
159 % 10 = 9
So 83918-28-9 is a valid CAS Registry Number.
83918-28-9Relevant academic research and scientific papers
Bernhart,Condamine,Demarne,Roncucci,Gagnol,Gautier,Serre
, p. 451 - 455 (1983)
The synthesis of new [(dialkylamino)alkyl]pyridylacetamides is reported. These compounds displayed a potent antiarrhythmic activity, as demonstrated on a model of myocardial infarction in the conscious dog. Structure-activity relationships are discussed within a series of 22 homologues, comparing relative antiarrhythmic properties and cardiac side effects. One of these compounds, 15, has been selected as a candidate for clinical evaluation in man.
